Evidence map›Paper›PMID 23922243›Full record

ArticleMolecular medicine (Cambridge, Mass.)2013

Immunomodulatory and antibacterial effects of cystatin 9 against Francisella tularensis.

Tonyia Eaves-Pyles, Jignesh Patel, Emma Arigi, Yingzi Cong, Anthony Cao, Nisha Garg, Monisha Dhiman, Richard B Pyles, Bernard Arulanandam, Aaron L Miller and 6 more

Open access · goldAbstract read
In one paragraph

Article in Molecular medicine (Cambridge, Mass.), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Tonyia Eaves-PylesDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas 77555, USA. tdeavesp@utmb.edu
Jignesh Patel
Emma Arigi
Yingzi Cong
Anthony Cao
Nisha Garg
Monisha Dhiman
Richard B Pyles
Bernard Arulanandam
Aaron L Miller
Vsevolod L Popov
Lynn Soong
Eric D Carlsen
Ciro Coletta
Csaba Szabo
Igor C Almeida
The University of Texas Medical Branch at Galveston · USThe University of Texas at El Paso · USThe University of Texas at San Antonio · US

Funding

TOXICOLOGY PROJECTG12RR008124 · NCRR · UNIVERSITY OF TEXAS EL PASO · PI AGUILERA, RENATO J · 1992 to 2011
$20.8M
NCRR NIH HHS 5G12RR008124-16A1NCRR NIH HHS 5G12RR008124-16A1S1NCRR NIH HHS G12 RR008124PHS HHS G12M0007592PHS HHS R21-A106877402
6 · The paper itself

Abstract

Cystatin 9 (CST9) is a member of the type 2 cysteine protease inhibitor family, which has been shown to have immunomodulatory effects that restrain inflammation, but its functions against bacterial infections are unknown. Here, we report that purified human recombinant (r)CST9 protects against the deadly bacterium Francisella tularensis (Ft) in vitro and in vivo. Macrophages infected with the Ft human pathogen Schu 4 (S4), then given 50 pg of rCST9 exhibited significantly decreased intracellular bacterial replication and increased killing via preventing the escape of S4 from the phagosome. Further, rCST9 induced autophagy in macrophages via the regulation of the mammalian target of rapamycin (mTOR) signaling pathways. rCST9 promoted the upregulation of macrophage proteins involved in antiinflammation and antiapoptosis, while restraining proinflammatory-associated proteins. Interestingly, the viability and virulence of S4 also was decreased directly by rCST9. In a mouse model of Ft inhalation, rCST9 significantly decreased organ bacterial burden and improved survival, which was not accompanied by excessive cytokine secretion or subsequent immune cell migration. The current report is the first to show the immunomodulatory and antimicrobial functions of rCST9 against Ft. We hypothesize that the attenuation of inflammation by rCST9 may be exploited for therapeutic purposes during infection.

Indexed as

AnimalsAnti-Bacterial AgentsCell MovementCystatinsFemaleFrancisella tularensisHumansImmunologic FactorsMacrophages, AlveolarMiceMice, Inbred BALB CPhagocytosisRecombinant ProteinsTularemiaVirulenceAnti-Bacterial AgentsCST9 protein, humanCystatinsImmunologic FactorsRecombinant Proteins

Identifiers

PMID23922243
PMCPMC3769527
OpenAlexW1531151498

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.